A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: A propensity score-matched cohort study

Annals of the Rheumatic Diseases

Volumn 75, Issue 1, 2016, Pages 96-102

  Závada, Jakub ^a   Uher, Michal ^b   Sisol, Katarína ^a   Forejtová, Šárka ^a   Jarošová, Kateřina ^a   Mann, Heřman ^a   Vencovský, Jiří ^a   Pavelka, Karel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; TUMOR NECROSIS FACTOR INHIBITOR; ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE REGISTRY; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RELAPSE; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; COMPARATIVE STUDY; CZECH REPUBLIC; DISABILITY; DISEASE FREE SURVIVAL; ECONOMICS; FOLLOW UP; MAINTENANCE CHEMOTHERAPY; METABOLISM; MIDDLE AGED; PROPENSITY SCORE; PROSPECTIVE STUDY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TIME FACTOR;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; C-REACTIVE PROTEIN; CZECH REPUBLIC; DISABILITY EVALUATION; DISEASE-FREE SURVIVAL; DRUG COSTS; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROPENSITY SCORE; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954317764     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205202     Document Type: Article

References (26)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
2. Davis JC, van der Heijde D, Dougados M, et al. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501.
3. Zink A, Braun J, Listing J, et al. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22.
4. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
5. Brandt J, Haibel H, Sieper J, et al. Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 2001;44:2936-7.
6. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
7. van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.
8. van der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
9. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
10. Baraliakos X, Haibel H, Listing J, et al. Radiographic progression in ankylosing spondylitis results after up to 8 years of infliximab treatment. Arthritis Rheum 2011;63(Suppl 10):546.
11. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
12. Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44.
13. Navarro-Compán V, Moreira V, Ariza-Ariza R, et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 2011;30:993-6.
14. Lee J, Noh JW, Hwang JW, et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol 2010;29:1149-54.
15. Gu X, Rosenbaum PR. Comparison of multivariate matching methods: Structures, distances, and algorithms. J Comput Graphical Stat 1993;2:405-20.
16. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
17. Stuart EA, Rubin DB. Best practices in quasi-experimental designs: matching methods for causal inference. In: Osborne J, ed. Best practices in quantitative methods, Chapter 11. Thousand Oaks: Sage Publications, 2007;155-76.
18. White IR, Kalaitzaki E, Thompson SG. Allowing for missing outcome data and incomplete uptake of randomised interventions, with application to an Internet-based alcohol trial. Stat Med 2011;30:3192-207.
19. Ho DE, Imai K, King G, et al. MatchIt: nonparametric preprocessing for parametric causal inference. J Statistical Software 2011;42:1-28.
20. Ara RM, Reynolds AV, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology (Oxford) 2007;46:1338-44.
21. van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1572-7.
22. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005.
23. Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 2005;32:80-5.
24. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
25. Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology 2004;43:1158-66.
26. Kobelt G, Andlin-Sobocki P, Maksymowch WP. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006;33:732-40.